WASHINGTON – The president’s spokesman says Trump still favors a plan to negotiate Medicare prices, but he did not mention it after a recent meeting with pharmaceutical executives, and his plans to speed FDA approval of new drugs may be hampered by his restrictions on new regulations and cuts to the federal workforce.
In-depth journalism.
In your home state.
In your inbox.
Sign up for CT Mirror's free daily briefings.
